Mohammed, M., Rashed, M., Ibrahem, M. (2022). Modern Diagnostic and Therapeutic Options for Retroperitoneal Fibrosis; Review article. The Egyptian Journal of Hospital Medicine, 88(1), 3637-3645. doi: 10.21608/ejhm.2022.249357
Mohammed Raafat Hassan Mohammed; Mostafa Mohmmad Mohammad Ebraheem Rashed; Mahmoud Saeed Mahmoud Ibrahem. "Modern Diagnostic and Therapeutic Options for Retroperitoneal Fibrosis; Review article". The Egyptian Journal of Hospital Medicine, 88, 1, 2022, 3637-3645. doi: 10.21608/ejhm.2022.249357
Mohammed, M., Rashed, M., Ibrahem, M. (2022). 'Modern Diagnostic and Therapeutic Options for Retroperitoneal Fibrosis; Review article', The Egyptian Journal of Hospital Medicine, 88(1), pp. 3637-3645. doi: 10.21608/ejhm.2022.249357
Mohammed, M., Rashed, M., Ibrahem, M. Modern Diagnostic and Therapeutic Options for Retroperitoneal Fibrosis; Review article. The Egyptian Journal of Hospital Medicine, 2022; 88(1): 3637-3645. doi: 10.21608/ejhm.2022.249357
Modern Diagnostic and Therapeutic Options for Retroperitoneal Fibrosis; Review article
Urology department, Ahmed Maher Teaching Hospital, Cairo, Egypt
Abstract
Background: Retroperitoneal fibrosis (RPF) is a rare condition characterized by inflammation and fibrous tissue deposition in the abdomen surrounding the aorta. This process has the potential to spread to nearby tissues, resulting in several complications, the most common and serious of which is a ureteral blockage. The most common cause is idiopathic retroperitoneal fibrosis (IRF), on the other hand, it can also be due to a variety of other elements. However, the illness’s main cause is still unknown. In retroperitoneal fibrosis, it surrounds the aorta and common iliac artery causing ureteral obstruction. Secondary spread of retroperitoneal fibrosis has been linked to malignant illness, medications, radiation exposure, and surgery. The predominance of retroperitoneal fibrosis is categorized as idiopathic, which is caused by an immune response. Idiopathic retroperitoneal fibrosis is nowadays thought to be a component of the illness group linked to immunoglobulin G4, a systemic inflammatory disease whose concept was only recently proposed. Conclusion: According to current research, over half of all instances of IRF might be due to newly found, illnesses linked to immunoglobulin G4 that are medically varied (IgG4-RD). Corticosteroid medications will be the first therapy for IRF, however, immunosuppressant drugs are also active therapy. This research adds a new understanding of concepts about etiopathogenesis, clinical manifestations, diagnosis, and therapy options for various forms of RPF.